Marker Therapeutics Inc (MRKR) - Net Assets
Based on the latest financial reports, Marker Therapeutics Inc (MRKR) has net assets worth $13.80 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($17.43 Million) and total liabilities ($3.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore MRKR asset base for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $13.80 Million |
| % of Total Assets | 79.13% |
| Annual Growth Rate | N/A |
| 5-Year Change | -61.81% |
| 10-Year Change | 171.59% |
| Growth Volatility | 474.04 |
Marker Therapeutics Inc - Net Assets Trend (1999–2025)
This chart illustrates how Marker Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Check MRKR intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Marker Therapeutics Inc (1999–2025)
The table below shows the annual net assets of Marker Therapeutics Inc from 1999 to 2025. For live valuation and market cap data, see market value of Marker Therapeutics Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $16.80 Million | -9.49% |
| 2024-12-31 | $18.56 Million | +32.06% |
| 2023-12-31 | $14.05 Million | -28.31% |
| 2022-12-31 | $19.60 Million | -55.44% |
| 2021-12-31 | $43.99 Million | +60.86% |
| 2020-12-31 | $27.34 Million | -37.97% |
| 2019-12-31 | $44.09 Million | -25.71% |
| 2018-12-31 | $59.34 Million | +1522.16% |
| 2017-12-31 | $3.66 Million | -40.85% |
| 2016-12-31 | $6.18 Million | +128.95% |
| 2015-12-31 | $-21.36 Million | -1986.71% |
| 2014-12-31 | $-1.02 Million | +88.33% |
| 2013-12-31 | $-8.77 Million | -54.73% |
| 2012-12-31 | $-5.67 Million | -63.76% |
| 2011-12-31 | $-3.46 Million | -5.74% |
| 2010-12-31 | $-3.27 Million | -419.95% |
| 2009-12-31 | $-629.39K | +79.18% |
| 2008-12-31 | $-3.02 Million | -80.52% |
| 2007-12-31 | $-1.67 Million | +44.18% |
| 2006-12-31 | $-3.00 Million | -35.15% |
| 2005-12-31 | $-2.22 Million | +9.03% |
| 2004-12-31 | $-2.44 Million | -279.05% |
| 2003-12-31 | $-643.75K | -238.19% |
| 2002-12-31 | $465.83K | +182.89% |
| 2000-12-31 | $-561.95K | -297.35% |
| 1999-12-31 | $-141.42K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Marker Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 45763675500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $16.67K | 0.10% |
| Other Components | $475.96 Million | 2833.64% |
| Total Equity | $16.80 Million | 100.00% |
Marker Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Marker Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Castor Maritime Inc
NASDAQ:CTRM
|
$18.84 Million |
|
Prakit Holdings Public Company Limited
BK:PRAKIT
|
$18.84 Million |
|
Gold Pacific Co. Ltd
KQ:038530
|
$18.85 Million |
|
Green River Holding Co Ltd
TWO:8444
|
$18.85 Million |
|
88 Energy Ltd
AU:88E
|
$18.83 Million |
|
Ordinary Fully Paid Deferred Settlement
AU:88EDA
|
$18.83 Million |
|
Pensonic Holdings Bhd
KLSE:9997
|
$18.83 Million |
|
Smart Concrete Public Company Limited
BK:SMART
|
$18.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Marker Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 18,558,406 to 16,796,814, a change of -1,761,592 (-9.5%).
- Net loss of 12,163,620 reduced equity.
- New share issuances of 9,863,883 increased equity.
- Other factors increased equity by 538,145.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.16 Million | -72.42% |
| Share Issuances | $9.86 Million | +58.72% |
| Other Changes | $538.14K | +3.2% |
| Total Change | $- | -9.49% |
Book Value vs Market Value Analysis
This analysis compares Marker Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.03x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1999-12-31 | $-141424.00 | $1.13 | x |
| 2000-12-31 | $-561951.00 | $1.13 | x |
| 2001-12-31 | $-173026.00 | $1.13 | x |
| 2002-12-31 | $465829.00 | $1.13 | x |
| 2003-12-31 | $-643745.00 | $1.13 | x |
| 2004-12-31 | $-0.12 | $1.13 | x |
| 2005-12-31 | $-23591.75 | $1.13 | x |
| 2006-12-31 | $-30852.32 | $1.13 | x |
| 2007-12-31 | $-9655.09 | $1.13 | x |
| 2008-12-31 | $-1548.07 | $1.13 | x |
| 2009-12-31 | $-383.31 | $1.13 | x |
| 2010-12-31 | $-986.88 | $1.13 | x |
| 2011-12-31 | $-903.02 | $1.13 | x |
| 2012-12-31 | $-1037.84 | $1.13 | x |
| 2013-12-31 | $-926.16 | $1.13 | x |
| 2014-12-31 | $-7.94 | $1.13 | x |
| 2015-12-31 | $-58.33 | $1.13 | x |
| 2016-12-31 | $0.83 | $1.13 | x |
| 2017-12-31 | $3.87 | $1.13 | x |
| 2018-12-31 | $31.08 | $1.13 | x |
| 2019-12-31 | $9.67 | $1.13 | x |
| 2020-12-31 | $5.81 | $1.13 | x |
| 2021-12-31 | $5.75 | $1.13 | x |
| 2022-12-31 | $2.35 | $1.13 | x |
| 2023-12-31 | $1.60 | $1.13 | x |
| 2024-12-31 | $2.07 | $1.13 | x |
| 2025-12-31 | $1.10 | $1.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Marker Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -72.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -342.96%
- • Asset Turnover: 0.19x
- • Equity Multiplier: 1.14x
- Recent ROE (-72.42%) is below the historical average (-61.86%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | 0.00% | -933.60% | 0.81x | 0.00x | $-1.11 Million |
| 2000 | 0.00% | -4060.96% | 0.26x | 0.00x | $-1.24 Million |
| 2001 | 0.00% | 0.00% | 0.00x | 0.00x | $-367.24K |
| 2002 | -490.52% | 0.00% | 0.00x | 1.63x | $-2.33 Million |
| 2003 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.71 Million |
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.44 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-768.03K |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.00 Million |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.72 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.89 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.40 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.76 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.68 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.29 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.66 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-30.78 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-31.93 Million |
| 2016 | -39.70% | 0.00% | 0.00x | 1.28x | $-3.07 Million |
| 2017 | -300.21% | -5998.99% | 0.04x | 1.42x | $-11.35 Million |
| 2018 | -249.34% | -71826.36% | 0.00x | 1.05x | $-153.89 Million |
| 2019 | -48.60% | -10050.92% | 0.00x | 1.05x | $-25.84 Million |
| 2020 | -104.98% | -6149.73% | 0.01x | 1.67x | $-31.44 Million |
| 2021 | -95.21% | -3372.68% | 0.02x | 1.55x | $-46.28 Million |
| 2022 | -152.70% | -851.87% | 0.10x | 1.76x | $-31.89 Million |
| 2023 | -58.61% | -248.76% | 0.19x | 1.22x | $-9.64 Million |
| 2024 | -57.82% | -162.82% | 0.30x | 1.19x | $-12.59 Million |
| 2025 | -72.42% | -342.96% | 0.19x | 1.14x | $-13.84 Million |
Industry Comparison
This section compares Marker Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $128,838,508
- Average return on equity (ROE) among peers: -63.38%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Marker Therapeutics Inc (MRKR) | $13.80 Million | 0.00% | 0.26x | $18.84 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $143.70 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $9.08 Million | -66.39% | 1.81x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $-18.49 Million | 0.00% | 0.00x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $-2.01 Million | 0.00% | 0.00x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $10.89 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $-22.51 Million | 0.00% | 0.00x | $3.66 Billion |
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-assoc… Read more